Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
Identifieur interne : 000705 ( an2020/Analysis ); précédent : 000704; suivant : 000706Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
Auteurs : David S. Fedson [Oman] ; Steven M. Opal [États-Unis] ; Ole Martin Rordam [Norvège]Source :
- mBio [ 2150-7511 ] ; 2020.
Descripteurs français
- KwdFr :
- Antagonistes du récepteur de type 2 de l'angiotensine-II (usage thérapeutique), Humains, Infections à coronavirus (), Infections à coronavirus (métabolisme), Infections à coronavirus (virologie), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (), Pneumopathie virale (métabolisme), Pneumopathie virale (virologie), Récepteur de type 2 à l'angiotensine-II (biosynthèse), Récepteurs viraux (biosynthèse).
- MESH :
- biosynthèse : Récepteur de type 2 à l'angiotensine-II, Récepteurs viraux.
- métabolisme : Infections à coronavirus, Peptidyl-Dipeptidase A, Pneumopathie virale.
- usage thérapeutique : Antagonistes du récepteur de type 2 de l'angiotensine-II, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Infections à coronavirus, Pneumopathie virale.
English descriptors
- KwdEn :
- Angiotensin II Type 2 Receptor Blockers (therapeutic use), Betacoronavirus, Coronavirus Infections (metabolism), Coronavirus Infections (therapy), Coronavirus Infections (virology), Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (metabolism), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Receptor, Angiotensin, Type 2 (biosynthesis), Receptors, Virus (biosynthesis).
- MESH :
- chemical , biosynthesis : Receptor, Angiotensin, Type 2, Receptors, Virus.
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , therapeutic use : Angiotensin II Type 2 Receptor Blockers, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Humans.
Abstract
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
DOI: 10.1128/mBio.00398-20
PubMed: 32198163
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000195
- to stream PubMed, to step Curation: 000195
- to stream PubMed, to step Checkpoint: 000656
- to stream Ncbi, to step Merge: 001409
- to stream Ncbi, to step Curation: 001409
- to stream Ncbi, to step Checkpoint: 001409
- to stream Main, to step Merge: 000707
- to stream Main, to step Curation: 000705
- to stream Main, to step Exploration: 000705
- to stream an2020, to step Extraction: 000705
Links to Exploration step
pubmed:32198163Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.</title><author><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><nlm:affiliation>57, chemin du Lavoir, Sergy Haut, France davidsfedson@gmail.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>57, chemin du Lavoir, Sergy Haut</wicri:regionArea><wicri:noRegion>Sergy Haut</wicri:noRegion></affiliation></author><author><name sortKey="Opal, Steven M" sort="Opal, Steven M" uniqKey="Opal S" first="Steven M" last="Opal">Steven M. Opal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Rordam, Ole Martin" sort="Rordam, Ole Martin" uniqKey="Rordam O" first="Ole Martin" last="Rordam">Ole Martin Rordam</name><affiliation wicri:level="3"><nlm:affiliation>Fyordgata 59, Trondheim, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Fyordgata 59, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32198163</idno><idno type="pmid">32198163</idno><idno type="doi">10.1128/mBio.00398-20</idno><idno type="wicri:Area/PubMed/Corpus">000195</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000195</idno><idno type="wicri:Area/PubMed/Curation">000195</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000195</idno><idno type="wicri:Area/PubMed/Checkpoint">000656</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000656</idno><idno type="wicri:Area/Ncbi/Merge">001409</idno><idno type="wicri:Area/Ncbi/Curation">001409</idno><idno type="wicri:Area/Ncbi/Checkpoint">001409</idno><idno type="wicri:Area/Main/Merge">000707</idno><idno type="wicri:Area/Main/Curation">000705</idno><idno type="wicri:Area/Main/Exploration">000705</idno><idno type="wicri:Area/an2020/Extraction">000705</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.</title><author><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name><affiliation wicri:level="1"><nlm:affiliation>57, chemin du Lavoir, Sergy Haut, France davidsfedson@gmail.com.</nlm:affiliation><country wicri:rule="url">Oman</country><wicri:regionArea>57, chemin du Lavoir, Sergy Haut</wicri:regionArea><wicri:noRegion>Sergy Haut</wicri:noRegion></affiliation></author><author><name sortKey="Opal, Steven M" sort="Opal, Steven M" uniqKey="Opal S" first="Steven M" last="Opal">Steven M. Opal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Rordam, Ole Martin" sort="Rordam, Ole Martin" uniqKey="Rordam O" first="Ole Martin" last="Rordam">Ole Martin Rordam</name><affiliation wicri:level="3"><nlm:affiliation>Fyordgata 59, Trondheim, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Fyordgata 59, Trondheim</wicri:regionArea><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author></analytic><series><title level="j">mBio</title><idno type="eISSN">2150-7511</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin II Type 2 Receptor Blockers (therapeutic use)</term><term>Betacoronavirus</term><term>Coronavirus Infections (metabolism)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Pneumonia, Viral (metabolism)</term><term>Pneumonia, Viral (therapy)</term><term>Pneumonia, Viral (virology)</term><term>Receptor, Angiotensin, Type 2 (biosynthesis)</term><term>Receptors, Virus (biosynthesis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes du récepteur de type 2 de l'angiotensine-II (usage thérapeutique)</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (virologie)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Pneumopathie virale ()</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (virologie)</term><term>Récepteur de type 2 à l'angiotensine-II (biosynthèse)</term><term>Récepteurs viraux (biosynthèse)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Receptor, Angiotensin, Type 2</term><term>Receptors, Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin II Type 2 Receptor Blockers</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Récepteur de type 2 à l'angiotensine-II</term><term>Récepteurs viraux</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Peptidyl-Dipeptidase A</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes du récepteur de type 2 de l'angiotensine-II</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.</div></front></TEI><affiliations><list><country><li>Norvège</li><li>Oman</li><li>États-Unis</li></country><region><li>Rhode Island</li><li>Trøndelag</li></region><settlement><li>Trondheim</li></settlement></list><tree><country name="Oman"><noRegion><name sortKey="Fedson, David S" sort="Fedson, David S" uniqKey="Fedson D" first="David S" last="Fedson">David S. Fedson</name></noRegion></country><country name="États-Unis"><region name="Rhode Island"><name sortKey="Opal, Steven M" sort="Opal, Steven M" uniqKey="Opal S" first="Steven M" last="Opal">Steven M. Opal</name></region></country><country name="Norvège"><region name="Trøndelag"><name sortKey="Rordam, Ole Martin" sort="Rordam, Ole Martin" uniqKey="Rordam O" first="Ole Martin" last="Rordam">Ole Martin Rordam</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000705 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000705 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= an2020
|étape= Analysis
|type= RBID
|clé= pubmed:32198163
|texte= Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/an2020/Analysis/RBID.i -Sk "pubmed:32198163" \
| HfdSelect -Kh $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |